case-patients submitted both acute-and convalescent-phase serum specimens; of these, two persons were positive for leptospirosis by MAT and by IgM ELISA on convalescent testing. Leptospirosis was considered probable in three paired serum samples by MAT, all of which were IgM ELISA-positive on convalescent testing; two were negative by MAT and by IgM ELISA testing. One case-patient submitted only an acutephase serum specimen, which was negative by both MAT and IgM ELISA. Analysis of additional blood specimens obtained from seven case-patients documented slightly elevated liver function tests in all seven patients and thrombocytopenia in three patients.
ampicillin should be used for persons with severe manifestations. Supportive therapy is indicated for treating dehydration, hypotension, hemorrhage, and renal failure (9 ) . Oral doxycycline (200 mg weekly) may provide effective chemoprophylaxis for persons with short-term exposure in environments associated with increased risk for infection (10 ) . Persons participating in recreational water activities in areas where leptospirosis is endemic may be at increased risk for the disease, particularly during periods of flooding, and should consider preventive measures such as wearing protective clothing and minimizing contact with potentially contaminated water (1 ) . Physicians should ask about a travel history and consider leptospirosis in the differential diagnosis for persons with a recent history of travel to areas with endemic disease.
Supplementary vaccination. In 1996, a total of 82 countries conducted National Immunization Days (NIDs)* (compared with 62 countries in 1995); since 1985, a cumulative total of 92 countries have conducted NIDs (Figure 1 ). Globally, during 1996, approximately 419 million children aged <5 years (approximately two thirds of the world's children aged <5 years) received oral poliovirus vaccine (OPV) during NIDs. By the end of 1996, all countries in Asia and Europe with endemic polio had conducted NIDs; globally, 17 countries with endemic polio had not conducted NIDs (15 of 42 countries in AFR with endemic polio and two of 23 countries with endemic polio in the Eastern Mediterranean Region [EMR] ). In addition, four countries in AFR conducted Subnational Immunization Days in 1996 in preparation for NIDs in 1997.
To rapidly interrupt poliovirus transmission and ensure coverage of migrant populations in border areas, NIDs in 1996 were coordinated between countries and among WHO regions. "Operation MECACAR" synchronized NIDs among 18 countries of the European Region (EUR) and EMR and achieved vaccination coverage of 95% (58 million children) (2 ) . NIDs conducted during December 1996 and January 1997 provided vaccination with OPV to 257 million children aged <5 years in Bangladesh, Bhutan, India, Myanmar, Nepal, Thailand (in the South East Asia Region [SEAR]), People's Republic of China, Vietnam (in the Western Pacific Region [WPR]), and Pakistan *Mass campaigns over a short period (days to weeks) in which two doses of OPV are administered to all children in the target age group, regardless of prior vaccination history, with an interval of 4-6 weeks between doses.
(in EMR). In India, the first round of NIDs in December 1996 achieved vaccination coverage of 117 million children aged <5 years, and the second round in January 1997 achieved vaccination coverage of 127 million children-this round was the largest vaccination campaign ever conducted. NIDs were conducted in 27 countries in Africa during 1996 as part of the "Kick Polio out of Africa" campaign; this campaign targeted three fourths of children aged <5 years living in sub-Saharan Africa (approximately 74 million children) (3 ) . In AFR, all countries with endemic polio except Democratic Republic of Congo (formerly Zaire) plan to conduct NIDs in 1997 (3 ). Mopping-up vaccination. Targeted supplementary house-to-house vaccination activities ("mopping-up" campaigns) were conducted in high-risk areas (areas identified as potential or known foci of continued poliovirus transmission based on surveillance for acute flaccid paralysis [AFP]). During 1995-1996, mopping-up vaccination in Yunnan Province, China, targeted approximately 3 million children aged <5 years. This campaign focused primarily on counties bordering Myanmar; these counties were targeted because of the identification of four imported cases from Myanmar in persons who were excreting wild poliovirus.
AFP surveillance. AFP surveillance is now conducted in 126 (86%) of 146 countries where polio is or recently was endemic. From 1995 to 1996, the number of countries conducting AFP surveillance increased from 120 to 137 (including 11 countries in which polio is not endemic).
Two important performance indicators for AFP surveillance are 1) the annual rate of nonpolio AFP per 100,000 children aged <15 years (target: >1 case per 100,000 population); and 2) the percentage of AFP cases for which adequate stool specimens have been collected (i.e., two stool specimens collected within 2 weeks of onset of paralysis [target: ≥80%]). From 1995 to 1996, the global rate for nonpolio AFP increased from 0.4 to 0.6, although region-specific rates varied substantially ( Table 1) . Rates of nonpolio AFP were <0.1 in SEAR and AFR, where AFP surveillance systems are being established.
The proportion of countries that have implemented and achieved high quality AFP surveillance (defined as an AFP rate of ≥1 per 100,000) also varied substantially by region. In the American Region (AMR), WPR, and SEAR, all countries where polio was or recently had been endemic conducted AFP surveillance; in AMR and WPR, 67% and 50%, respectively, of countries reported a rate of nonpolio AFP of ≥1. AFP surveillance had not yet been established in 15 (36%) of the 42 countries in AFR, three (13%) of the 23 in EMR, and two (11%) of the 18 in EUR. In all regions except AMR and WPR, <25% of countries reported nonpolio AFP rates of ≥1.
Laboratory network. In addition to the 16 regional and six specialized reference laboratories, the number of national laboratories participating in the Global Polio Laboratory Network increased from 65 in 1995 to 67 in 1996. In 1996, a process was initiated to formally accredit all national laboratories for participation in the WHO Poliomyelitis Eradication Program. Accreditation will ensure quality and facilitate the use of standardized procedures and reagents.
Impact of Strategies on Polio Incidence
In 1996, a total of 3997 polio cases were reported globally, a decrease of 43% from the 7032 cases reported in 1995. In 1996, a total of 155 countries reported zero cases of polio (compared with 150 countries in 1995), 18 countries reported one to 10 cases (compared with 27 countries in 1995), and 27 countries reported >10 cases (compared with 30 countries in 1995); the 14 countries that made no report primarily included small countries, island nations, and war-affected countries. In AFR, the number of polio cases reported in 1996 decreased 13% from 1995 (from 2192 to 1898 cases). The impact of NIDs conducted during the 1996 "Kick Polio out of Africa" campaign on disease incidence can be evaluated in 1997. In AMR during 1996, no indigenous wild poliovirus was isolated for the fifth consecutive year, despite continuing high quality AFP surveillance and testing of adequate stool specimens obtained from 1485 (76%) of 1954 patients with AFP.
In EMR, the number of reported polio cases declined 53% from 1995 to 1996 (789 to 373), despite improvements in surveillance for AFP (Table 1 ). However, wild poliovirus continued to circulate in Pakistan and Egypt. In Egypt, endemic transmission continued with 99 virologically confirmed cases of polio (attributable to serotypes 1 and 3) in 18 (67%) of the 27 governorates; the 99 cases were an increase from the 71 cases reported in 1995. In Pakistan, although the number of polio cases decreased from 460 in 1995 to 223 in 1996, wild poliovirus was isolated from patients in all provinces in 1996.
The number of reported cases in EUR decreased from 1995 (210 cases) to 1996 (191 cases). However, 167 (87%) of the 191 cases in 1996 were associated with a large outbreak resulting from a wild poliovirus importation into Albania (138 cases with 16 deaths), Yugoslavia (Kosovo, 24 cases reported), and Greece (five cases reported). In countries participating in "Operation MECACAR" (2 ), the number of cases continued to decrease from 1995 (53) to 1996 (19).
The number of reported cases in SEAR decreased 67% from 1995 (3349) to 1996 (1116) (4 ), mainly reflecting the impact of NIDs in India conducted in December 1995 and January 1996. The number of cases reported in India decreased 69% from 1995 (3263) to 1996 (1005). High priorities in SEAR include rapid improvement of AFP surveillance to monitor the effect of NIDs and target future supplementary vaccination, and efforts are being initiated to strengthen AFP surveillance in six of eight countries in the region.
In WPR, 419 (8%) of 5288 AFP cases reported in 1996 were confirmed as polio (compared with 492 [9%] of 5650 cases in 1995). Of the 419 cases, 21 (5%) were confirmed based on wild poliovirus isolation, and three of the 21 were imported into southwestern China from Myanmar. No indigenous wild poliovirus was isolated in China during 1996. The other 18 wild-virus-associated polio cases were reported from Cambodia (15), Vietnam (two), and Laos (one). The areas in Cambodia and southern Vietnam in which viruses were found constitute the last known remaining reservoir of wild poliovirus transmission in WPR. During May-June 1997, a cross-border mopping-up operation was conducted in areas of Cambodia, Laos, and Vietnam to interrupt regional transmission.
all children aged <5 years worldwide. In addition, an increasing number of countries participated in multinational, synchronized NIDs to target the remaining foci of transmission of wild poliovirus. As a result of the efforts to expand supplementary vaccination activities, the number of reported polio cases rapidly decreased in many countries. Despite this progress, efforts to develop AFP surveillance-including highquality laboratory support-have lagged, and the highest priorities now are to improve surveillance and conduct NIDs in the remaining countries with endemic polio. The rapid development of complete and timely AFP surveillance, particularly in the countries with endemic disease in the AFR, EMR, and SEAR, is an urgent priority to achieve the goal of global polio eradication by the year 2000. The global incidence of polio may decline further during 1997 as a result of the planned implementation of NIDs for the first time in all except one of the remaining countries with endemic polio.
War-affected or politically isolated countries (e.g., North Korea, Somalia, southern Sudan, and Democratic Republic of Congo) are reservoirs from which wild virus may continue spreading into bordering or distant polio-free countries, and intensification of the eradication initiative in these countries is critical to the achievement of global eradication. The polio outbreak involving Albania, Yugoslavia, and Greece underscored how countries previously polio-free may remain at risk for poliovirus importation because of suboptimal vaccination coverage or inadequate vaccination of subpopulations.
Although most of the resources to implement polio eradication have been provided by the countries with endemic polio, success of this initiative requires support from other sources, and international and interregional coordination. Projected resource requirements include approximately $175 million in external support to sustain polio eradication activities globally during 1997, and total external support of $1 billion for 1997-2005. External support also must continue for countries and regions where the incidence of polio has reached low levels to ensure interruption of the final chains of poliovirus transmission and to permit the eventual certification of eradication.
Prevalence of Cardiovascular Disease Risk-Factor Clustering
Among Persons Aged ≥45 Years -Louisiana, 1991-1995 Cardiovascular Disease Risk-Factor Clustering -Continued Cardiovascular disease (CVD), including coronary heart disease, stroke, and hypertensive disease, is the leading cause of death in Louisiana and in the United States and, in 1994, accounted for 43.7% and 45.2% of all deaths among persons aged ≥45 years in Louisiana and in the United States, respectively. The primary risk factors for CVD are hypertension, high cholesterol, diabetes, overweight, cigarette smoking, and physical inactivity. The first four of these risk factors may cluster in some persons and have been identified as components of a syndrome known as metabolic cardiovascular syndrome (1 ) or the "deadly quartet" (2 ) . This syndrome is characterized by a persistent state of insulin resistance and compensatory hyperinsulinemia that may be etiologically related to the four risk factors. Persons with one of the four risk factors are at increased risk for having any of the other three (3 ). To determine the prevalence of risk-factor clustering among older residents of Louisiana, CDC analyzed data from the 1991, 1992, 1993, and 1995 Louisiana Behavioral Risk Factor Surveillance System (BRFSS).* This report summarizes the results of this analysis, which documented a prevalence of clustering of the four risk factors among 1.7% of the respondents aged ≥45 years.
The BRFSS is a population-based, random-digit-dialed telephone survey of the civilian, noninstitutionalized U.S. population aged ≥18 years. Respondents were asked their weight and height and whether they had ever been told by a health-care professional that they had high blood pressure, high cholesterol, or diabetes. Body mass index (BMI), defined as the ratio of weight in kilograms to height in meters squared, was used to determine overweight. Overweight was defined as a BMI of >27.3 for women and >27.8 for men. Presence of any of the other three risk factors was determined by a positive response to the other questions. Data were weighted, and prevalence estimates and standard errors were calculated using SUDAAN.
In Louisiana, complete data were available for 2068 (78%) of the 2646 respondents aged ≥45 years during the 4 years. Data were incomplete for 578 (22%) respondents, including 532 (92%) who reported their cholesterol levels had never been checked. Persons who reported their cholesterol level had been checked were more likely than those who did not to also report having high blood pressure (40.7% and 26.8%, respectively) and/or diabetes (12.3 % and 7.9%, respectively). Among the total respondent population of 2646 persons, the prevalence of high blood pressure and diabetes was 38.1% and 11.4%, respectively. This analysis is based on data from the 2068 respondents who had complete data and is generalizable to Louisiana residents aged >45 years who have ever had their cholesterol level checked.
Overall prevalence estimates of the four risk factors ranged from 12.3% for diabetes to 40.2% for high blood pressure (Table 1) . At least one of the four risk factors was reported by 73% of respondents, and 37% had two or more of the risk factors. Clustering of the four risk factors was estimated at 1.7% (Table 2) . Although cell sizes were small, prevalence of clustering of the four risk factors ranged from 0.7% for white men to 4.8% for black women. Editorial Note: From 1991 through 1994, the average annual age-adjusted CVD death rate among Louisiana women and men aged ≥45 years (593.3 and 987.3 per 100,000 population, respectively) were the second and fourth highest, respectively, of the 50 states and the District of Columbia † . The findings in this report indicate that, during 1991-1995, 1.7% of Louisiana residents aged ≥45 years self-reported risk factors compatible with metabolic cardiovascular syndrome and that prevalence of clustering of CVD risk factors varied substantially by sex and race. The race-specific prevalence of clustering of the four risk factors among black women was seven times that of white men and nearly three times that of white women, reflecting, in part, the higher prevalence of overweight among black women.
In this report, high blood pressure was the most prevalent CVD risk factor for both men and women aged ≥45 years. In the United States, less than one fourth of persons with hypertension have their blood pressure under control (4 ). Because control of hypertension does not return CVD risk to that of normotensives, primary prevention of hypertension provides the best opportunity to reduce CVD risk associated with this risk factor. Strategies for the primary prevention of hypertension include attaining and maintaining optimal weight, engaging in moderate physical activity, and limiting intake of salt and alcohol (5 ) .
Excessive caloric intake leading to overweight has been postulated as the event leading to the emergence of the other risk factors in metabolic cardiovascular syndrome (6 ) . Therefore, reductions in the prevalence of overweight and individual weight loss may have the greatest impact on CVD risk and risk-factor clustering. Even small decreases in weight among persons who are overweight may decrease the prevalence of high blood pressure, elevated cholesterol levels, and diabetes (3 ). Comprehensive public health efforts to reduce the prevalence of overweight should include environmental interventions such as reducing the fat and caloric content of processed foods and changing food preparation methods in institutional settings (e.g., schools, worksites, restaurants, and hospitals). Efforts to improve eating and exercise behaviors should also continue to be encouraged through public health campaigns such as eating at least five servings of fruits and vegetables each day and initiatives to improve physical activity levels (7 ). The Office of Public Health, Louisiana Department of Health and Hospitals, is initiating programs to increase the proportion of residents who meet the Surgeon General's recommendations for moderate physical activity and who eat five servings of fruits and vegetables each day to reduce the burden of overweight, diabetes, and CVD. 6 In the MMWR Recommendations and Reports, "Prevention of Hepatitis A Through Active or Passive Immunization-Recommendations of the Advisory Committee on Immunization Practices (ACIP)," the second full paragraph on page 12 (i.e., the last paragraph in the section titled "Immune Globulin") contained errors regarding the recommended delay between administration of immune globulin and measlesmumps-rubella vaccine. The paragraph should read: "IG does not interfere with the immune response to either oral poliovirus vaccine or yellow fever vaccine, or, in general, to inactivated vaccines. However, IG can interfere with the response to other live, attenuated vaccines (e.g., measles-mumps-rubella [MMR] and varicella) when vaccines are administered individually or as combination vaccines. Administration of MMR should be delayed for at least 3 months, and varicella vaccine should be delayed for at least 5 months, after administration of IG for hepatitis A prophylaxis. IG should not be administered within 2 weeks after the administration of MMR or within 3 weeks after administration of varicella vaccine unless the benefits of IG administration exceed the benefits of vaccination (77 ). If IG is administered within 2 weeks after administration of MMR or within 3 weeks after administration of varicella vaccine, the person should be revaccinated, but not sooner than 3 months after the IG administration for MMR or 5 months for varicella vaccine (77 )."
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